JENA, Germany—Carl Zeiss Meditec AG (ISIN: DE 0005313704) reported an increase in revenue for all strategic business units and regions after 12 months of fiscal year 2017/18. Revenue increased by 7.6 percent, or 11.1 percent when adjusted for currency effects, to €1,280.9 million, up from €1,189.9 million in the prior year. Earnings before interest and taxes (EBIT) rose to €197.1 million, versus €180.8 million year ago. The EBIT margin remained stable at 15.4 percent compared with prior year.

“We achieved our sales forecast, which we had already raised in July 2018—in spite of negative currency effects. In fiscal year 2017/18 we gained further market shares in both ophthalmology and microsurgery. What is particularly encouraging is that all regions and business segments contributed—the performance of the Americas and Asia/Pacific regions was particularly strong,” said Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG.

The company’s strategic business unit (SBU) Ophthalmic Devices increased its revenue by 6.0 percent after 12 months of fiscal year 2017/18 (adjusted for currency effects: 9.3 percent), to €933.3m, compared with €880.5m in the same period of the prior year. The laser systems business for vision correction and the diagnostics business developed particularly well, Carl Zeiss Meditec said. There was also continued solid demand for premium and standard intraocular lenses for the treatment of cataracts.

Revenue in the Microsurgery SBU grew by 12.3 percent, or 16.5 percent when adjusted for currency effects, to €347.6 million, compared with €309.4 million in the prior year. Carl Zeiss Meditec said the growth was largely attributable to new products for the neurosurgery and dental segments.


Revenue in the EMEA region increased by 4.0 percent, or 5.4 percent with currency effects, to €378.1 million, up from €363.4 million the prior year. Development in the core markets Germany and France was stable. Increases were achieved in the U.K., Southern Europe and some Eastern European markets.

A positive trend was also recorded in the Americas region. Revenue increased to €406.5 million, versus €378.2 million year ago. This growth amounted to 7.5 percent, or 14.4 percent when adjusted for currency effects, and thus accelerated significantly compared with the prior year. This is primarily due to a continued positive trend in the U.S. market, the company said.

The Asia/Pacific (APAC) region, led by China and Korea, grew by 10.7 percent, or 13.2 percent when adjusted for currency effects, to €496.3 million versus €448.2 million year ago.